M.D. Greg Keenan - 27 Feb 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
SVP, Chief Medical Officer
Signature
/s/ Greg Keenan, M.D.
Issuer symbol
AUPH
Transactions as of
27 Feb 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:13:25 UTC
Previous filing
03 Feb 2026
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Keenan Greg SVP, Chief Medical Officer #140, 14315 - 118 AVENUE, EDMONTON, ALBERTA, CANADA /s/ Greg Keenan, M.D. 03 Mar 2026 0002044006

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Award $0 +40,586 +33% $0.000000 162,518 27 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Employee Stock Option (right to buy) Award $0 +67,870 $0.000000 67,870 27 Feb 2026 Common Stock 67,870 $13.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2 One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.